METHODS: Systematic review and meta-analysis.
METHODS: GO Patients treated with selenium compared to placebo.
METHODS: Clinical activity score (CAS), Graves\' orbitopathy quality of life (GO-QOL), eye symptoms and signs, and adverse events.
RESULTS: Out of 1684 records screened, four randomised controlled trials were included. Selenium was superior at 6 months in lowering the CAS (MD = -1.27, 95% confidence interval [CI] [-1.68, -0.85], p < .0001]), improving total GO-QOL (RR = 2.54, 95% CI [1.69-3.81], p < .00001), and improving the visual and the psychological functioning scores (MD = 10.84, 95% CI [4.94-16.73], p = .003), (MD = 12.76, 95% CI [8.51-17.00], p < .00001) respectively. Similarly, it significantly improved these outcomes at 12 months. It also showed a significant decrease in the palpebral aperture at 6 months (MD = -1.49, 95% CI [-2.90, -0.08], p = .04). However, no significant differences were observed in proptosis, soft tissue involvement, ocular motility, and adverse effects.
CONCLUSIONS: Selenium is effective in reducing CAS and improving the palpebral aperture and GO-QOL in patients with GO. Additionally, it is safe and has promising therapeutic implications. However, further research is needed to validate its long-term efficacy and safety.
方法:系统评价和荟萃分析。
方法:与安慰剂相比,用硒治疗的GO患者。
方法:临床活动评分(CAS),Graves\'眼眶病生活质量(GO-QOL),眼部症状和体征,和不良事件。
结果:在筛选的1684条记录中,纳入4项随机对照试验.硒在6个月时在降低CAS方面优于(MD=-1.27,95%置信区间[CI][-1.68,-0.85],p<.0001]),提高总GO-QOL(RR=2.54,95%CI[1.69-3.81],p<.00001),改善视觉和心理功能评分(MD=10.84,95%CI[4.94-16.73],p=.003),(MD=12.76,95%CI[8.51-17.00],p<.00001)。同样,它在12个月时显著改善了这些结局.它还显示6个月时的睑孔明显减小(MD=-1.49,95%CI[-2.90,-0.08],p=.04)。然而,没有观察到显着的差异,在突起,软组织受累,眼运动性,和不利影响。
结论:硒可有效降低GO患者的CAS,改善眼睑孔径和GO-QOL。此外,它是安全的,具有良好的治疗意义。然而,需要进一步的研究来验证其长期疗效和安全性.